BioCentury | Nov 20, 2020

Nov. 19 Quick Takes: Olema’s IPO, plus venture rounds for Imago, Medable,  China deal for AUM-Newsoara and Qiming’s $1.2B fund

Olema posts big gain after $209M IPOShares of Olema Pharmaceuticals Inc. (NASDAQ:OLMA) rose $30 (158%) to $49 in their first day of trading after the company raised $209 million through the sale of 11 million...
BioCentury | Nov 21, 2019

Entinostat-derived LSD1 and HDAC dual inhibitor for pediatric glioma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer An HDAC and LSD1 inhibitor could treat diffuse intrinsic pontine glioma, a subtype of pediatric brain cancer. A dual HDAC and LSD1 inhibitor tool compound, derived from the HDAC...
BioCentury | Sep 19, 2019
Tools & Techniques

Atomwise's JV spree

Drug developers signing up to partner with Atomwise for hit discovery and lead optimization said deal structures made it attractive to take the plunge on the AI company's emerging technology. Last week, Atomwise Inc. announced...
BioCentury | Jun 20, 2019
Targets & Mechanisms

Moving beyond the active site: why allostery is newly in fashion

A new crop of companies is creating tools to systematize development of allosteric protein inhibitors, finally moving industry beyond the one-off compounds that have been found by accident. Allosteric pockets on proteins have long been...
BioCentury | May 31, 2019
Targets & Mechanisms

Targeting cancer evolution offers a way to foil drug resistance

A growing crop of researchers and companies are tackling cancer drug resistance by preempting tumors’ tendencies to adapt, rather than responding to resistance after it develops. Though still in their infancy, these therapies could get...
BioCentury | Mar 21, 2019
Financial News

Imago to deploy $40M series B for Phase II trials

Imago raised $40 million Thursday in a tranched series B round led by new investor Omega Funds to support completing Phase II trials of its lead compound, IMG-7289, for hematological indications. An Imago BioSciences Inc....
BioCentury | Dec 6, 2018
Translation in Brief

Opening chromatin: long-term detriment?

An Institute for Research in Biomedicine team has shown increasing chromatin accessibility in cancer could promote tumor aggressiveness, not reduce tumor mutation burden (TMB) as previously thought. The findings, reported last month in Nature Cell...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
BioCentury | Nov 2, 2018
Targets & Mechanisms

FDA’s pediatric target picks

FDA is looking ahead of industry in its guideline on targets for pediatric oncology, which includes more than 50 not yet in company pipelines in a list of over 220 the agency has its eye...
BioCentury | Oct 31, 2018
Distillery Therapeutics


INDICATION: Breast cancer Cell culture and mouse studies suggest inhibiting KDM4B alone or in combination with PI3K could help treat PTEN-deficient triple-negative breast cancer (TNBC). In a PTEN-deficient TNBC cell line, two siRNAs against KDM4B...
Items per page:
1 - 10 of 85